People with ADHD had a 70% higher risk of death from any cause in a 19-study meta-analysis, with excess deaths from suicide, injury and natural causes.
|Podcasts|July 16, 2021
Compassionate Billing is Combatting Traditional Healthcare and Putting the Patient First Again, Per Florian Otto of Cedar
Author(s)Briana Contreras
In this week's episode, Associate Editor, Briana Contreras spoke with Dr. Florian Otto, co-founder and CEO for Cedar, a complete healthcare financial engagement platform. Dr. Otto discussed the topic of compassionate billing and how this particular payment model is becoming triumphant over traditional healthcare payment models where patients are experiencing an increase in insurance deductibles and out-of-pocket medical expenses.
Advertisement
To listen to more episodes featured on Tuning Into The C-Suite, visit us on
Advertisement
Related to this article
Bronchiectasis affected 221.6 per 100,000 people in the U.S. over five years, which is higher than earlier national estimates, according to a study published in CHEST.
Cepheid’s Xpert Respiratory Panel, which tests one swab for nine viruses and four bacteria, is now certified for sale in Europe under the IVDR.
A study of 1,068 adults found whole-blood NAD fell in those with cardiovascular disease and hypertension but did not decline with age.
Adding Sunharbo (asundexian), a first-in-class factor XI inhibitor, to single or dual antiplatelet therapy reduces ischemic stroke risk without increasing the risk of major bleeding.
In this discussion, University College London colleagues Joshua Stott, Ph.D., professor of aging and clinical psychology and research assistant Lucy Corrigan, who led the work while at the University of Liverpool, talk about their recent meta-analysis linking ADHD to a higher risk of death from all causes, including suicide, injury and natural causes.
The American Academy of Sleep Medicine’s first update since 2007 favors generic drugs, caffeine, light and naps, and advises against benzodiazepines.
People with advanced Parkinson’s disease who also have a sleep disorder cost about $50,000 a year to treat, $13,000 more than similar patients without one, according to an AbbVie-funded claims analysis.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
A new strategy for secondary stroke prevention gets boost from FDA approval
2
Low blood NAD levels track heart disease and hypertension, not aging
3
Patience and persistence define one Yale gastroenterologist’s approach to MASLD
4
Sleep disorders add $13,000 a year to advanced Parkinson’s care costs
5